source
- Estuary Biotherapeutics raises $103M to advance gene therapies for polycystic kidney diseaseEstuary Biotherapeutics announced it has exited stealth mode after securing $103 million in financing to move two gene‑therapy candidates into clinical testing for autosomal dominant polycystic kid…
- Oxford biotech OMass Therapeutics secures $310 million to advance genetic adrenal disorder programOxford-based OMass Therapeutics announced a $310 million private financing round, one of the largest recent fundraises for a UK biotech. The capital will fund the development of therapies targetin…